EpimAb Biotherapeutics raises $74 mln
EpimAb Biotherapeutics said June 5 that it raised $74 million in Series B funding co-led by by SDIC Fund and Sherpa Healthcare Partners. Also taking part in the round was SCVC, further private investment entities, and the A round investors. EpimAb, of Shanghai, China, is a biopharmaceutical company specializing in bispecific antibodies.
5 June 2019•4 mins read
